BACKGROUND AND PURPOSE: We investigated whether administration of @entity4465 , a free radical scavenger, before or during @entity3479 (tPA) can enhance early recanalization in a major @entity432 . METHODS: The YAMATO study ( @entity3479 and @entity4465 Combination Therapy) is an investigator-initiated, multicenter (17 hospitals in Japan), prospective, randomized, and open-label study. @entity1 with @entity64 secondary to occlusion of the M1 or M2 portion of the middle cerebral artery and within 4.5 hours of the onset were studied. The subjects were randomly allocated to the early group (intravenous @entity4465 [30 mg] was started before or during tPA) and the late group ( @entity4465 was started after tPA and the assessment of early recanalization). RESULTS: One-hundred sixty-five @entity1 (96 @entity1 ; median age [interquartile range], of 78 [69-85] years) were randomized 1:1 to either the early group (82 @entity1 ) or the late group (83 @entity1 ). Primary outcome, defined as an early recanalization 1.5 hour after tPA, was observed in 53% of the early group and in 53% of the late group (P=1.000). About secondary outcomes, the rate of significant recanalization of >= 50% was not different between the 2 groups (28% versus 34%; P=0.393). The symptomatic @entity1779 has occurred in 4 @entity1 (5%) in the early group and in 2 @entity1 (2%) in the late group (P=0.443). The favorable outcome (modified Rankin Scale score of 0-2) at 3 months was also similar between the groups (53% versus 57%; P=0.738). CONCLUSIONS: The timing of @entity4465 infusion does not affect the rate of early recanalization, symptomatic @entity1779 , or favorable outcome after tPA therapy. CLINICAL TRIAL REGISTRATION: URL: http://www.umin.ac.jp/ctr/index-j.htm. Unique identifier: UMIN000006330.

YAMATO Study ( @entity3479 and XXXX Combination Therapy).

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'men'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity4465 :: ('MESH:C005435', 'Chemical') :: ['edaravone', 'Edaravone'] @entity432 :: ('MESH:D001157', 'Disease') :: ['arterial occlusion'] @entity3479 :: ('5327', 'Gene') :: ['tissue-type plasminogen activator', 'Tissue-Type Plasminogen Activator'] @entity1779 :: ('MESH:D002543', 'Disease') :: ['intracerebral hemorrhage']
@entity4465 :: (MESH:C005435,Chemical) :: ['Edaravone']
